rs2274515
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The ENST00000244546.4(PEX6):c.2117G>A(p.Cys706Tyr) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0621 in 1,612,834 control chromosomes in the GnomAD database, including 4,649 homozygotes. In-silico tool predicts a benign outcome for this variant. 11/16 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).
Frequency
Consequence
ENST00000244546.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PEX6 | NM_000287.4 | c.2364G>A | p.Val788Val | splice_region_variant, synonymous_variant | 13/17 | ENST00000304611.13 | NP_000278.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PEX6 | ENST00000244546.4 | c.2117G>A | p.Cys706Tyr | missense_variant, splice_region_variant | 11/15 | 1 | ENSP00000244546.4 | |||
PEX6 | ENST00000304611.13 | c.2364G>A | p.Val788Val | splice_region_variant, synonymous_variant | 13/17 | 1 | NM_000287.4 | ENSP00000303511.8 |
Frequencies
GnomAD3 genomes AF: 0.0660 AC: 10041AN: 152066Hom.: 559 Cov.: 32
GnomAD3 exomes AF: 0.0901 AC: 22604AN: 250900Hom.: 1650 AF XY: 0.0865 AC XY: 11744AN XY: 135778
GnomAD4 exome AF: 0.0617 AC: 90120AN: 1460650Hom.: 4085 Cov.: 33 AF XY: 0.0629 AC XY: 45724AN XY: 726690
GnomAD4 genome AF: 0.0661 AC: 10052AN: 152184Hom.: 564 Cov.: 32 AF XY: 0.0696 AC XY: 5178AN XY: 74406
ClinVar
Submissions by phenotype
not specified Benign:3
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 30, 2013 | - - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 06, 2018 | Variant summary: Variant c.2364G>A (p.Val788Val) affects a non-conserved neucleotide resulting a synonymous change in the ATPase, AAA-type, core domain of the encoded protein. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.086 in 276948 control chromosomes in the gnomAD database, including 1712 homozygotes. The observed variant frequency is approximately 44.65 fold of the estimated maximal expected allele frequency for a pathogenic variant in PEX6 causing Zellweger Syndrome phenotype (0.0019), strongly suggesting that the variant is benign. c.2364G>A has been reported in the literature in individuals affected with Zellweger Syndrome and authors listed variant as SNP and neutral (Yik_2009). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Multiple clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar and classified the variant as benign (2 labs)/likely benign (1 lab). Based on the evidence outlined above, the variant was classified as benign. - |
Peroxisome biogenesis disorder 4A (Zellweger) Benign:2
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 10, 2021 | - - |
not provided Benign:2
Benign, no assertion criteria provided | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Oct 23, 2015 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jun 13, 2018 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Zellweger spectrum disorders Benign:1
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Heimler syndrome 2 Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 10, 2021 | - - |
Peroxisome biogenesis disorder Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Peroxisome biogenesis disorder 4B Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 10, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at